{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Restored to CR, did not develop GVHD"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Were not restored to CR, did not develop GVHD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"To compute the current multiple myeloma free survival curve in order to account for patients who relapse and are restored to remission through DLI.","groups":[{"description":"This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma","id":"OG000","title":"Relapsed Multiple Myeloma"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This group consists of participants with residual disease either because they did not reach CR from salvage and transplant conditioning or because they were given this dose at the time of progression","reportingStatus":"POSTED","timeFrame":"3 years","title":"Number of Participants Who Relapse That Are Restored to Remission (CR)","type":"SECONDARY","unitOfMeasure":"Participants"}